Company says new facility will support increasing demand for Gibco cell culture products.

Life Technologies will invest $20 million into the construction of a new cell culture facility at its existing manufacturing site in Scotland. The firm says the expansion will support increasing demand for its Gibco® cell culture products for biological drug research, development, and production, and will secure the supply chain for Europe, the Americas, and Asia.  

The investment is accompanied by ongoing support form Scotland’s development agency, Scottish Enterprise, and will increase Life’s global manufacturing network for its Advanced Granulated Technology (AGT™) and dry powder media under the Gibco brand. “Our investment in this facility now provides a secure, complementary supply chain source for media used in life-saving therapeutics while also addressing the growing global demand for our cell culture media products,” states Gregory T. Lucier, Life Technologies’ chairman and CEO.

Life already employs 500 people at the Inchinnan site near Glasgow, which is its headquarters for Europe, Africa, and the Middle East. The firm says AGT media is the fastest-growing segment in the Gibco cell culture portfolio. 

Previous articleTDI Licenses PBI’s Pressure Cycling Technology for Cancer Biomarker Diagnostic Services
Next articleVectura, Novartis’ COPD Therapy Succeeds in Fourth Phase III Study